{"id":"tofogliflozin","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Sodium/glucose cotransporter 2","category":"target"},{"label":"SLC5A2","category":"gene"},{"label":"SLC5A1","category":"gene"},{"label":"Active","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"},{"label":"Hypoglycemic Agents","category":"pharmacology"},{"label":"Sodium-Glucose Transporter 2 Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TOFOGLIFLOZIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:54:14.478832+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:54:21.473702+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TOFOGLIFLOZIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:54:22.245064+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sodium/glucose cotransporter 2 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:54:22.819449+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2105711/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:54:22.721297+00:00"}},"allNames":"apleway","offLabel":[],"synonyms":["tofogliflozin","tofogliflozin hydrate","deberza","apleway","CSG452"],"timeline":[{"date":"2014-03-24","type":"positive","source":"DrugCentral","milestone":"PMDA approval"}],"approvals":[{"date":"2014-03-24","orphan":false,"company":"","regulator":"PMDA"}],"brandName":"Apleway","ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000}],"mechanism":{"target":"Sodium/glucose cotransporter 2","targets":[{"gene":"SLC5A2","source":"DrugCentral","target":"Sodium/glucose cotransporter 2","protein":"Sodium/glucose cotransporter 2"},{"gene":"SLC5A1","source":"DrugCentral","target":"Sodium/glucose cotransporter 1","protein":"Sodium/glucose cotransporter 1"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Apleway inhibits the sodium/glucose cotransporter 2 (SGLT2) in the proximal convoluted tubule of the nephron, reducing glucose reabsorption and increasing urinary glucose excretion."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4892","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TOFOGLIFLOZIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TOFOGLIFLOZIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T16:01:41.241860","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:54:24.607619+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"bexagliflozin","drugSlug":"bexagliflozin","fdaApproval":"2023-01-20","patentExpiry":"May 14, 2032","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"canagliflozin","drugSlug":"canagliflozin","fdaApproval":"2013-03-29","patentExpiry":"Jun 3, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"dapagliflozin","drugSlug":"dapagliflozin","fdaApproval":"2014-01-08","patentExpiry":"Sep 9, 2040","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"empagliflozin","drugSlug":"empagliflozin","fdaApproval":"2014-08-01","patentExpiry":"Oct 3, 2034","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"ertugliflozin","drugSlug":"ertugliflozin","fdaApproval":"2017-12-19","patentExpiry":"Jul 13, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"sotagliflozin","drugSlug":"sotagliflozin","fdaApproval":"2023-05-26","patentExpiry":"Oct 7, 2030","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"tofogliflozin","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"bexagliflozin","brandName":"bexagliflozin","genericName":"bexagliflozin","approvalYear":"2023","relationship":"same-target"},{"drugId":"canagliflozin","brandName":"canagliflozin","genericName":"canagliflozin","approvalYear":"2013","relationship":"same-target"},{"drugId":"dapagliflozin","brandName":"dapagliflozin","genericName":"dapagliflozin","approvalYear":"2014","relationship":"same-target"},{"drugId":"empagliflozin","brandName":"empagliflozin","genericName":"empagliflozin","approvalYear":"2014","relationship":"same-target"},{"drugId":"ertugliflozin","brandName":"ertugliflozin","genericName":"ertugliflozin","approvalYear":"2017","relationship":"same-target"},{"drugId":"sotagliflozin","brandName":"sotagliflozin","genericName":"sotagliflozin","approvalYear":"2023","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05469659","phase":"PHASE2","title":"Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)","status":"RECRUITING","sponsor":"Shinshu University","startDate":"2021-09-22","conditions":["T2DM (Type 2 Diabetes Mellitus)","Metformin","SGLT2-Inhibitors"],"enrollment":120,"completionDate":"2026-10-30"},{"nctId":"NCT02649465","phase":"PHASE4","title":"SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD","status":"COMPLETED","sponsor":"Kanazawa University","startDate":"2015-11-11","conditions":["Non-alcoholic Fatty Liver Disease"],"enrollment":40,"completionDate":"2021-06-30"},{"nctId":"NCT02537834","phase":"PHASE4","title":"Tofogliflozin GLP-1 Analogue Combination Trial","status":"COMPLETED","sponsor":"Kowa Company, Ltd.","startDate":"2015-08","conditions":["Type 2 Diabetes Mellitus"],"enrollment":65,"completionDate":"2017-10"},{"nctId":"NCT02201004","phase":"PHASE4","title":"TOFO Insulin Combination Trial","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-06","conditions":["Type 2 Diabetes Mellitus"],"enrollment":211,"completionDate":"2016-10"},{"nctId":"NCT02284269","phase":"","title":"Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Pharmaceuticals and Medical Devices Agency, Japan","startDate":"2014-10","conditions":["Diabetes Mellitus, Type 2"],"enrollment":18000,"completionDate":""},{"nctId":"NCT02528019","phase":"PHASE4","title":"Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors","status":"UNKNOWN","sponsor":"Kurume University","startDate":"2015-08","conditions":["Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications"],"enrollment":100,"completionDate":"2018-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"P8DD8KX4O4","CHEBI":"CHEBI:136041","UMLSCUI":"C3501434","chemblId":"CHEMBL2105711","ChEMBL_ID":"CHEMBL2110731","KEGG_DRUG":"D09978","DRUGBANK_ID":"DB11824","PDB_CHEM_ID":" RT2","PUBCHEM_CID":"46908928","IUPHAR_LIGAND_ID":"9395","SECONDARY_CAS_RN":"1201913-82-7","MESH_SUPPLEMENTAL_RECORD_UI":"C575086"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"4.7 hours","clearance":"2.07 mL/min/kg","bioavailability":"98%","fractionUnbound":"0.46%","volumeOfDistribution":"0.63 L/kg"},"publicationCount":196,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"2014","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2014-03-24T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:54:24.607619+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}